Concepts (186)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Protease Inhibitors | 15 | 2023 | 105 | 3.450 |
Why?
|
| HIV-1 | 18 | 2023 | 721 | 2.850 |
Why?
|
| Antiviral Agents | 17 | 2025 | 324 | 2.490 |
Why?
|
| Viral Nonstructural Proteins | 14 | 2022 | 93 | 2.280 |
Why?
|
| HIV Protease | 12 | 2023 | 120 | 2.180 |
Why?
|
| Hepacivirus | 12 | 2022 | 141 | 2.160 |
Why?
|
| Protease Inhibitors | 13 | 2022 | 102 | 2.000 |
Why?
|
| Drug Resistance, Viral | 18 | 2025 | 157 | 1.810 |
Why?
|
| Quinoxalines | 7 | 2022 | 37 | 1.770 |
Why?
|
| Anti-HIV Agents | 5 | 2019 | 154 | 1.560 |
Why?
|
| Macrocyclic Compounds | 3 | 2021 | 8 | 1.300 |
Why?
|
| Crystallography, X-Ray | 19 | 2025 | 433 | 1.270 |
Why?
|
| Structure-Activity Relationship | 19 | 2021 | 373 | 1.200 |
Why?
|
| Drug Design | 13 | 2022 | 136 | 0.950 |
Why?
|
| Sulfonamides | 9 | 2022 | 127 | 0.920 |
Why?
|
| Molecular Structure | 14 | 2021 | 385 | 0.910 |
Why?
|
| Models, Molecular | 17 | 2025 | 1149 | 0.820 |
Why?
|
| Darunavir | 6 | 2023 | 30 | 0.760 |
Why?
|
| Furans | 2 | 2020 | 33 | 0.690 |
Why?
|
| Hepatitis C | 3 | 2021 | 151 | 0.670 |
Why?
|
| Virus Replication | 2 | 2012 | 321 | 0.610 |
Why?
|
| Viral Proteins | 4 | 2025 | 263 | 0.560 |
Why?
|
| Catalytic Domain | 11 | 2024 | 199 | 0.530 |
Why?
|
| Positive Transcriptional Elongation Factor B | 3 | 2016 | 8 | 0.520 |
Why?
|
| Molecular Dynamics Simulation | 6 | 2024 | 120 | 0.480 |
Why?
|
| vif Gene Products, Human Immunodeficiency Virus | 2 | 2012 | 13 | 0.450 |
Why?
|
| Enterovirus D, Human | 2 | 2025 | 11 | 0.450 |
Why?
|
| Cysteine Endopeptidases | 2 | 2025 | 94 | 0.430 |
Why?
|
| Cyclopropanes | 5 | 2022 | 50 | 0.430 |
Why?
|
| Protein Binding | 13 | 2025 | 1603 | 0.430 |
Why?
|
| Stereoisomerism | 5 | 2019 | 69 | 0.420 |
Why?
|
| Oxazolidinones | 2 | 2010 | 14 | 0.410 |
Why?
|
| Carrier Proteins | 3 | 2014 | 707 | 0.390 |
Why?
|
| Molecular Docking Simulation | 4 | 2020 | 79 | 0.370 |
Why?
|
| Mutation | 12 | 2025 | 2612 | 0.370 |
Why?
|
| Lactams, Macrocyclic | 3 | 2022 | 25 | 0.370 |
Why?
|
| Proline | 3 | 2022 | 44 | 0.370 |
Why?
|
| Leucine | 3 | 2022 | 61 | 0.360 |
Why?
|
| Amides | 4 | 2020 | 55 | 0.360 |
Why?
|
| Aminoisobutyric Acids | 2 | 2022 | 9 | 0.350 |
Why?
|
| Aminopeptidases | 2 | 2022 | 27 | 0.350 |
Why?
|
| Serine Proteases | 2 | 2021 | 12 | 0.340 |
Why?
|
| Piperidines | 2 | 2010 | 63 | 0.330 |
Why?
|
| Flavonoids | 2 | 2010 | 75 | 0.320 |
Why?
|
| Drug Resistance, Multiple, Viral | 4 | 2018 | 14 | 0.320 |
Why?
|
| Substrate Specificity | 7 | 2024 | 339 | 0.320 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2019 | 205 | 0.310 |
Why?
|
| HEK293 Cells | 3 | 2020 | 622 | 0.290 |
Why?
|
| HIV Infections | 4 | 2023 | 969 | 0.280 |
Why?
|
| Oxazoles | 1 | 2006 | 10 | 0.260 |
Why?
|
| Humans | 34 | 2025 | 63445 | 0.250 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2019 | 864 | 0.250 |
Why?
|
| Peptide Hydrolases | 2 | 2023 | 77 | 0.240 |
Why?
|
| HeLa Cells | 6 | 2019 | 536 | 0.230 |
Why?
|
| Dipeptides | 2 | 2020 | 67 | 0.230 |
Why?
|
| Ligands | 4 | 2019 | 416 | 0.230 |
Why?
|
| Enzyme Inhibitors | 2 | 2021 | 373 | 0.230 |
Why?
|
| Cell Line | 4 | 2019 | 2040 | 0.210 |
Why?
|
| Protein Conformation | 6 | 2025 | 779 | 0.210 |
Why?
|
| Flavivirus | 1 | 2022 | 8 | 0.200 |
Why?
|
| Benzoic Acid | 1 | 2022 | 2 | 0.190 |
Why?
|
| Zika Virus | 1 | 2022 | 35 | 0.190 |
Why?
|
| Small Molecule Libraries | 2 | 2013 | 58 | 0.190 |
Why?
|
| Zika Virus Infection | 1 | 2022 | 36 | 0.190 |
Why?
|
| Human T-lymphotropic virus 1 | 1 | 2021 | 5 | 0.180 |
Why?
|
| Serine Endopeptidases | 2 | 2022 | 84 | 0.180 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2021 | 37 | 0.170 |
Why?
|
| Sulfones | 1 | 2020 | 39 | 0.170 |
Why?
|
| Carbamates | 7 | 2020 | 26 | 0.170 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2020 | 47 | 0.170 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2020 | 10 | 0.160 |
Why?
|
| Tryptamines | 1 | 2019 | 13 | 0.160 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2021 | 618 | 0.160 |
Why?
|
| Phenylurea Compounds | 1 | 2019 | 32 | 0.160 |
Why?
|
| Virus Diseases | 1 | 2021 | 120 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 9 | 3 | 2016 | 6 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 124 | 0.160 |
Why?
|
| Cytidine Deaminase | 2 | 2012 | 86 | 0.160 |
Why?
|
| Hydrogen Bonding | 1 | 2019 | 129 | 0.150 |
Why?
|
| Drug Discovery | 4 | 2021 | 95 | 0.150 |
Why?
|
| Rats | 1 | 2021 | 1980 | 0.140 |
Why?
|
| Peptides, Cyclic | 1 | 2017 | 22 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2014 | 337 | 0.130 |
Why?
|
| Dengue Virus | 1 | 2017 | 99 | 0.130 |
Why?
|
| Exoribonucleases | 1 | 2016 | 30 | 0.120 |
Why?
|
| Binding Sites | 3 | 2018 | 905 | 0.120 |
Why?
|
| Kinetics | 5 | 2018 | 763 | 0.120 |
Why?
|
| Enterovirus Infections | 2 | 2025 | 12 | 0.110 |
Why?
|
| Isoquinolines | 1 | 2014 | 33 | 0.110 |
Why?
|
| Genotype | 1 | 2016 | 663 | 0.110 |
Why?
|
| Viral Structural Proteins | 1 | 2013 | 17 | 0.100 |
Why?
|
| Hyphae | 1 | 2013 | 16 | 0.100 |
Why?
|
| Oligopeptides | 3 | 2015 | 132 | 0.100 |
Why?
|
| Morphogenesis | 1 | 2013 | 113 | 0.100 |
Why?
|
| Piperazines | 1 | 2013 | 81 | 0.100 |
Why?
|
| Cell Adhesion | 1 | 2013 | 209 | 0.100 |
Why?
|
| Candida albicans | 1 | 2013 | 72 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 1 | 2013 | 78 | 0.100 |
Why?
|
| Amino Acid Sequence | 3 | 2021 | 1592 | 0.090 |
Why?
|
| Cell Survival | 2 | 2012 | 575 | 0.090 |
Why?
|
| Fluorescence Resonance Energy Transfer | 3 | 2009 | 79 | 0.090 |
Why?
|
| RNA Interference | 2 | 2005 | 618 | 0.090 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 2022 | 35 | 0.090 |
Why?
|
| Cyclin T | 1 | 2010 | 1 | 0.080 |
Why?
|
| Genes, Viral | 1 | 2010 | 57 | 0.080 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2010 | 48 | 0.080 |
Why?
|
| Indoles | 2 | 2012 | 110 | 0.080 |
Why?
|
| Molecular Sequence Data | 2 | 2010 | 1991 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 98 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1617 | 0.070 |
Why?
|
| Cytosine Deaminase | 1 | 2008 | 6 | 0.070 |
Why?
|
| RNA, Small Interfering | 2 | 2005 | 921 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 130 | 0.070 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2021 | 93 | 0.070 |
Why?
|
| Gene Products, tat | 2 | 2004 | 14 | 0.070 |
Why?
|
| Histones | 1 | 2010 | 481 | 0.070 |
Why?
|
| Animals | 3 | 2021 | 20663 | 0.060 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2005 | 6 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2009 | 988 | 0.060 |
Why?
|
| Static Electricity | 2 | 2016 | 167 | 0.060 |
Why?
|
| RNA Transport | 1 | 2004 | 31 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2016 | 381 | 0.050 |
Why?
|
| Computer Simulation | 2 | 2017 | 477 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 190 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2008 | 795 | 0.050 |
Why?
|
| Halogenation | 1 | 2022 | 4 | 0.050 |
Why?
|
| Fluorine | 1 | 2022 | 9 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2013 | 2157 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 1 | 2022 | 173 | 0.040 |
Why?
|
| Orthomyxoviridae | 1 | 2021 | 26 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2016 | 936 | 0.040 |
Why?
|
| APOBEC-3G Deaminase | 2 | 2012 | 21 | 0.040 |
Why?
|
| Male | 1 | 2021 | 29891 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2012 | 673 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 177 | 0.040 |
Why?
|
| Computational Biology | 1 | 2021 | 356 | 0.040 |
Why?
|
| Peptides | 1 | 2022 | 574 | 0.040 |
Why?
|
| Crystallography | 2 | 2009 | 26 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 240 | 0.030 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 2 | 2010 | 13 | 0.030 |
Why?
|
| Aprotinin | 1 | 2017 | 11 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 491 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2021 | 707 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2016 | 51 | 0.030 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2017 | 265 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2016 | 196 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2016 | 134 | 0.030 |
Why?
|
| Microsomes | 1 | 2013 | 11 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2020 | 721 | 0.030 |
Why?
|
| Polystyrenes | 1 | 2013 | 33 | 0.030 |
Why?
|
| Nematoda | 1 | 2013 | 34 | 0.030 |
Why?
|
| Isoindoles | 1 | 2012 | 3 | 0.020 |
Why?
|
| Lactams | 1 | 2012 | 18 | 0.020 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2012 | 11 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 1 | 2012 | 32 | 0.020 |
Why?
|
| HIV Integrase | 1 | 2012 | 7 | 0.020 |
Why?
|
| Ribonuclease H | 1 | 2012 | 18 | 0.020 |
Why?
|
| Chromatin | 1 | 2016 | 608 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2013 | 390 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2021 | 3035 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2010 | 52 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 2010 | 81 | 0.020 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2010 | 78 | 0.020 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2009 | 7 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2010 | 188 | 0.020 |
Why?
|
| Lopinavir | 1 | 2007 | 5 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2007 | 16 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2007 | 94 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2007 | 294 | 0.020 |
Why?
|
| Mice | 2 | 2013 | 10844 | 0.010 |
Why?
|
| RNA-Induced Silencing Complex | 1 | 2005 | 67 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 2003 | 8 | 0.010 |
Why?
|
| Biopolymers | 1 | 2004 | 71 | 0.010 |
Why?
|
| Peptide Library | 1 | 2003 | 37 | 0.010 |
Why?
|
| Automation | 1 | 2003 | 54 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2003 | 39 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2004 | 276 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2003 | 139 | 0.010 |
Why?
|
| Algorithms | 1 | 2008 | 1003 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 2004 | 410 | 0.010 |
Why?
|
| Nucleic Acid Conformation | 1 | 2003 | 239 | 0.010 |
Why?
|
| Nanostructures | 1 | 2004 | 177 | 0.010 |
Why?
|
| Base Sequence | 1 | 2004 | 1331 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2003 | 308 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 423 | 0.010 |
Why?
|
| Models, Biological | 1 | 2003 | 1180 | 0.010 |
Why?
|